OSTX - NYSE

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%

HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.00M

EPS-0.5200

P/E Ratio-2.73

Earnings Date03/30/2026

ostx

EPS

Last Annual Value

-0.52

3-Year CAGR

-16%

5-Year CAGR

-275%

10-Year CAGR

-94%

Adjust for Inflation

OS Therapies Incorporated Competitors Analysis of EPS

OSTX · NYSE

Company	EPS	CAGR 3Y	CAGR 5Y	CAGR 10Y
OS Therapies Incorporated NYSE:OSTX	-0.52	N/A	N/A	N/A
CervoMed Inc. NASDAQ:CRVO	-2.02	N/A	N/A	N/A
MediciNova, Inc. NASDAQ:MNOV	-0.24	N/A	N/A	N/A
Aligos Therapeutics, Inc. NASDAQ:ALGS	-2.45	N/A	N/A	N/A
Cue Biopharma, Inc. NASDAQ:CUE	-8.40	N/A	N/A	N/A
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO	-0.33	N/A	N/A	N/A
Werewolf Therapeutics, Inc. NASDAQ:HOWL	-1.32	N/A	N/A	N/A
Spruce Biosciences, Inc. NASDAQ:SPRB	-50.83	N/A	N/A	N/A
Coeptis Therapeutics, Inc. NASDAQ:COEP	-2.81	N/A	N/A	N/A
NRx Pharmaceuticals, Inc. NASDAQ:NRXP	-1.34	N/A	N/A	N/A
Outlook Therapeutics, Inc. NASDAQ:OTLK	-1.79	N/A	N/A	N/A

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

HIDDEN

Intrinsic Value

Current Price: $1.42

Related Guides

Blog Categories

Continue your OSTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.